Funapide - Xenon Pharmaceuticals

Drug Profile

Funapide - Xenon Pharmaceuticals

Alternative Names: TV-45070; XEN 402; XPF 001; XPF-002

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Teva Pharmaceutical Industries; Xenon Pharmaceuticals
  • Class Analgesics; Benzodioxoles; Fluorobenzenes; Furans; Indoles; Non-opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors; Nav1.8 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythromelalgia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Postherpetic neuralgia
  • Discontinued Dental pain; Erythromelalgia; Musculoskeletal pain; Pain

Most Recent Events

  • 28 Mar 2018 Xenon Pharmaceutical and Teva terminate its licence agreement for Funapide
  • 24 Oct 2017 Discontinued - Phase-II for Erythromelalgia in USA (Topical) (Xenon pipeline and Teva Pharmaceutical Industries pipeline, October 2017)
  • 24 Oct 2017 Phase-II clinical trials in Neuropathic pain before October 2017 (Topical) (Teva Pharmaceutical Industries pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top